XNAS · Healthcare · Biotechnology
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.24 | -0.38 | -58.33% | $0 | ❌ Miss | -0.18% | +16.37% | — |
| 2026-05-14 | Q1 2026 | -5.37 | -7.30 | -35.94% | $0 | ❌ Miss | -1.27% | +0.80% | -2.40% |
| 2025-11-17 |
| Q3 2025 |
| -6.63 |
| -5.76 |
| +13.12% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2024-11-15 | Q3 2024 | -5.00 | -12.50 | -150.00% | $0 | ❌ Miss | +14.18% | +18.36% | -2.00% |
| 2024-08-14 | Q2 2024 | — | -336.00 | — | $0 | — | +1.81% | +19.86% | +7.00% |
| 2024-05-15 | Q1 2024 | — | -1025.00 | — | $0 | — | +12.68% | +3.66% | -72.04% |
| 2024-04-01 | Q4 2023 | — | -2375.00 | — | $0 | — | -14.54% | -37.74% | -39.41% |
| 2023-11-14 | Q3 2023 | — | -2700.00 | — | $0 | — | +14.97% | +25.15% | +5.39% |
Showing last 8 quarters.